Sona Nanotech Inc. announced further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the "Study") which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response. These data relate to the follow-up biomarker analysis performed on the previously reported cohort of animals that showed a statistically significant synergistic effect in the shrinking of both treated and untreated tumors in animals bearing multiple tumors after treatment with the combination of Sona's targeted hyperthermia therapy ("THT") and interleukin-2 ("IL-2"), an immunotherapy agent widely used to treat human cancer patients. The fluorescence-activated cell sorting ("FACS") analysis of the tumor infiltrating cells looking at two panels of 12 biomarkers demonstrated a statistically significant cytotoxic T-cell infiltrate in both treated tumors and the untreated (contralateral) tumors, confirming a systemic immune response, consistent with an abscopal effect, in the treated mice treated with the combined THT and IL-2 therapy that is not seen in the other groups.

It is also notable that treated tumors also demonstrated significantly more memory T-cells, which would be consistent with an enduring systemic immune response. With hypothesis proven in these triple negative breast cancer mouse experiments, the lab team is looking forward to assessing whether similar promising results can be shown in melanoma and colorectal cancer murine models. The Study consisted of 26 mice bearing multiple triple negative breast cancer tumors, including a control group of six, seven given IL-2 only, and seven given THT only, as well as the cohort of six mice that were administered the combination of the generation of hyperthermia followed by intratumoral injections with IL-2. The Study's next step is to assess the therapy's ability to generate similar results in melanoma and coloreCTal cancer mouse models and determine the extent to which it eliminates untreated distant tumors for these cancers.

Following the melanoma and colorectAL experiments in the Study, regulatory permission to conduct human trials will require certain satisfactory pre-clinical safety and biocompatibility studies, amongst other potential work. The Company has received guidance on its preclinical study plan from both a pre-submission meeting with the Food and Drug Administration and its EXCITE International panel of senior physicians and payor. organization representatives in the United States.

The results discussed in this release are preliminary and have not been subject to peer review. Upon completion, the Company expects that the full Study will be submitted for peer review and scientific journal publication. Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications.

It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.